Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Targeting the SphK1/S1P/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesis

Fig. 2

Inhibition of SphK1 suppresses HCC progression in DEN-treated mice. DEN-injected mice were treated with vehicle (veh) or PF-543 (PF) for 12 weeks. A The number and maximal diameter of visible liver tumors were quantified from macroscopic images. B The number and maximal diameter of intrahepatic liver tumors were quantified from the scanning of the entire H&E-stained liver tissue sections. C Cell proliferation in non-tumorous (NT) and tumorous (T) liver tissues was stained and quantified using Ki67 immunohistochemistry; scale bar = 50 μm. Data are expressed as mean ± SD. n = 9. *p < 0.05; **p < 0.01; ***p < 0.001

Back to article page